Brain stimulation that pauses during sleep for essential tremor
Tests deep brain stimulation that switches off automatically during sleep in essential tremor.
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Registry title
- Circadian Adaptive DBS in Essential Tremor
- Status
- Recruiting
- People taking part
- 25 people, planned
- Started
- 1 May 2025
- Expected to end
- Oct 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Circadian Adaptive DBS
- Conventional DBS
- Record updated
- 30 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with essential tremor who already have a Medtronic Percept deep brain stimulation (DBS) device. It tests turning stimulation off automatically during sleep.
- Age
- 21 to 89 years
- Sex
- All sexes
- Disease stage
- Essential tremor confirmed by a movement disorders specialist, using criteria set by the Movement Disorders Society.
- Earlier treatment
- People must already have DBS leads in the VIM area of the thalamus (one or both sides), connected to a Medtronic Percept DBS device. DBS must have improved tremor by 30% on the TRS or TETRAS at least 3 months after implantation. DBS must be set up in a monopolar setting that allows ongoing brain sensing (C+1- or C+2-).
Main reasons for not taking part
- Not able to follow the study plan
- Pregnancy
- Current active thoughts of suicide (Yes to #2-5 on C-SSRS)
- Personality or mood symptoms that study staff believe would get in the way of the study
- Not able to give informed consent
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Diagnosis of Essential Tremor confirmed by a Movement Disorders specialist following established criteria recommended by the Movement Disorders Society
- Patients implanted with unilateral or bilateral VIM DBS leads attached to the Medtronic Percept DBS device for the treatment of Essential Tremor
- Patients with clinical benefit of DBS as defined by a 30% improvement on the TRS or TETRAS at least 3 months after DBS implantation
- DBS programmed in a monopolar configuration allowing chronic brain sensing (C+1- or C+2- in ring mode or any direction)
- Be between 21 and 89 years old
- Ability to give informed consent for the study
Who cannot take part
- Pregnancy: all women of childbearing potential will have a negative urine pregnancy test prior to undergoing the study
- Inability to comply with the study protocol
- Current active suicidal ideation (Yes to #2-5 on C-SSRS)
- Any personality or mood symptoms that study personnel believe will interfere with study requirements
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 89 years old?
Where in United States
- Norman Fixel Institute for Neurological DiseasesGainesville, United StatesContact: Julia C Gonzalez, BATaking people
About the trial
What the trial wants to find out
Deep brain stimulation (DBS) of the thalamus is an effective treatment for medically refractory essential tremor (ET). DBS involves delivering continuous stimulation to the brain through electrodes permanently implanted in the thalamus. Despite proven effectiveness, the long-term benefit of DBS can wane over time (habituation) and side effects, including paresthesia and dysarthria, often limit the amplitude of the stimulation, resulting in suboptimal control of tremor. In clinical practice, many groups advise patients to switch their devices off at night to avoid habituation and reduce side effects. However, manually turning off the device at night can result in uncontrolled tremor when the patient moves at night.
Read full original descriptionShow less
This study aims to develop an algorithm that automatically turns off stimulation when a patient is asleep, based on circadian brain signals. Turning off stimulation could potentially improve the therapy by limiting adverse effects, increasing efficacy, reducing the risk of habituation, and prolonging battery life. This study will evaluate the feasibility, safety, and tolerability of circadian adaptive DBS.
The 2 groups in the trial
- Adaptive DBS, Then Conventional DBSTreatment being tested
Participants will initially have their DBS programmed to automatically turn off during sleep for 2 weeks. Then, they will transition to continuous stimulation for another 2 weeks.
Treatment: Circadian Adaptive DBS and Conventional DBS
- Conventional DBS, then Adaptive DBSTreatment being tested
Participants will initially have their DBS programmed with continuous stimulation for 2 weeks. Then, they will transition to having their DBS automatically turned off during sleep for another 2 weeks.
Treatment: Circadian Adaptive DBS and Conventional DBS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Circadian Adaptive Deep Brain Stimulation in Essential Tremor
- Plain-language title
- Brain stimulation that pauses during sleep for essential tremorGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06635811, who can take part
- Record updated
- 30 July 2026